Compare Lam Research Corporation (LRCX) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lam Research Corporation vs Medtronic PLC — how do they compare? Lam Research Corporation trades at $318.84 (market cap $401.19B), while Medtronic PLC trades at $88.48 (market cap $112.24B). The key difference: Lam Research Corporation is far larger — about 3.6× Medtronic PLC's market cap, and Medtronic PLC pays the higher dividend (3.28%). Which is the better fit depends on your goals — on Pluang, investors hold Lam Research Corporation for 60 Days and Medtronic PLC for 63 Days on average.
| LRCX | MDT | |
|---|---|---|
Market Cap | $401.19B | $112.24B |
Volume | 8,960,892 | 105,663,236 |
Sector | Technology | Health |
52-Week High | $433.33 | $105.35 |
52-Week Low | $131.37 | $73.75 |
Typical Hold Time | 60 Days | 63 Days |
Enterprise Value | $399.35B | $131.58B |
Dividend Yield | 0.41% | 3.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lam Research (LRCX) trades at $320.59, down 2.71% on the day, amid a bearish technical signal despite strong fundamentals. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $1.82 surpassing the $1.69 estimate, and maintains high profitability with a net income margin of 31.27%. Revenue growth is accelerating, reaching $18.44 billion in 2025, supported by AI-driven demand for semiconductor equipment. Analyst consensus remains strongly bullish with a $375.68 price target, though technical indicators show mixed signals with key support at $314.
LRCX presents a compelling long-term investment opportunity driven by AI infrastructure spending and operational efficiency, but faces near-term volatility from technical bearishness and macroeconomic headwinds. Risks include cyclical semiconductor demand and competitive pressures, yet strong institutional support and consistent earnings outperformance underpin upside potential toward analyst targets.
Medtronic (MDT) trades at $87.75, up 2.62% today, with strong analyst support (60.8% buy ratings) and a $97.80 consensus price target suggesting 11.5% upside. The stock shows consistent earnings beats in recent quarters and maintains a 49-year dividend growth streak. However, technical indicators signal bearish momentum with resistance near $89-90. Revenue growth accelerated to $33.54B in 2025 with net margins improving to 13.93%, though debt levels have risen to 31.1% of assets.
MDT presents a compelling value opportunity with attractive dividend yield and earnings momentum, but faces near-term technical headwinds and increasing leverage. The upcoming Q3 earnings report and MiniMed separation will be critical catalysts. Investors should weigh the strong fundamental recovery against bearish technical signals and monitor debt management closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lam Research Corporation
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
